Volume | 5,181,805 |
|
|||||
News | (1) | ||||||
Day High | 5.175 | Low High |
|||||
Day Low | 4.96 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Ardelyx Inc | ARDX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
5.02 | 4.96 | 5.175 | 5.14 | 5.02 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
20,343 | 5,181,805 | US$ 5.06 | US$ 26,243,506 | - | 1.70 - 5.175 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:51:27 | formt | 270 | US$ 5.13 | USD |
Ardelyx (ARDX) Options Flow Summary
Ardelyx Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.19B | 232.14M | - | 52.16M | -67.21M | -0.29 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ardelyx News
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARDX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.11 | 5.175 | 4.11 | 4.71 | 4,916,822 | 1.02 | 24.82% |
1 Month | 4.04 | 5.175 | 3.43 | 4.24 | 4,153,567 | 1.09 | 26.98% |
3 Months | 4.86 | 5.175 | 3.16 | 3.96 | 6,455,261 | 0.27 | 5.56% |
6 Months | 3.65 | 5.175 | 3.16 | 3.93 | 5,711,960 | 1.48 | 40.55% |
1 Year | 1.89 | 5.175 | 1.70 | 3.69 | 6,555,277 | 3.24 | 171.43% |
3 Years | 6.40 | 9.23 | 0.4902 | 2.54 | 6,193,003 | -1.27 | -19.84% |
5 Years | 2.50 | 10.4343 | 0.4902 | 2.74 | 3,940,794 | 2.63 | 105.2% |
Ardelyx Description
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis. |